2S-amino-1-(4-benzyl-piperidin-1-yl)-3,3-dimethyl-butan-1-one | 325459-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2S-amino-1-(4-benzyl-piperidin-1-yl)-3,3-dimethyl-butan-1-one
• 英文别名: (2S)-2-amino-1-(4-benzylpiperidin-1-yl)-3,3-dimethylbutan-1-one
• CAS: 325459-63-0
• 化学式: C₁₈H₂₈N₂O
• 分子量: 288.433
• InChiKey: LJVPDSVGMBXHPB-MRXNPFEDSA-N

物化性质

• 沸点：
  431.2±28.0 °C(Predicted)
• 密度：
  1.040±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2S-amino-1-(4-benzyl-piperidin-1-yl)-3,3-dimethyl-butan-1-one 在 palladium on activated charcoal N-羟基-7-氮杂苯并三氮唑 、 氢气 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-2-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [(S)-1-(4-benzyl-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide
  参考文献：
  名称：

  Structure–activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2′ and P3′ side chains

  摘要：

  Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to both the P2' and P3' side chains. Enzyme inhibition and antibacterial activity data revealed that a variety of substituents are tolerated at the P2' and P3' positions of the inhibitor backbone. The data from this study highlights the potential for modification at the P2' and P3' positions to optimise the physicochemical properties. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00533-x
• 作为产物：
  描述：

  Cbz-L-叔亮氨酸 在 palladium on activated charcoal N-羟基-7-氮杂苯并三氮唑 、 氢气 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2S-amino-1-(4-benzyl-piperidin-1-yl)-3,3-dimethyl-butan-1-one
  参考文献：
  名称：

  Structure–activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2′ and P3′ side chains

  摘要：

  Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to both the P2' and P3' side chains. Enzyme inhibition and antibacterial activity data revealed that a variety of substituents are tolerated at the P2' and P3' positions of the inhibitor backbone. The data from this study highlights the potential for modification at the P2' and P3' positions to optimise the physicochemical properties. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00533-x

文献信息

• ANTIBACTERIAL AGENTS
  申请人：Vernalis (Oxford) Ltd

  公开号：EP1210330B1

  公开（公告）日：2005-04-20
• US6908911B1
  申请人：——

  公开号：US6908911B1

  公开（公告）日：2005-06-21
• [EN] ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTERIENS
  申请人：BRITISH BIOTECH PHARM

  公开号：WO2001010835A1

  公开（公告）日：2001-02-15

  Selected compounds of formula (I) are antibacterial agents: formula (I) wherein R2 represents a substituted or unsubstituted C1-C6 alkyl, cycloalkyl (C1-C6 alkyl)- or aryl (C1-C6 alkyl)- group, and A represents a group of formula (IA), or (IB) wherein R4 represents the side chain of a natural or non-natural alpha amino acid, and R5 and R6 are each independently hydrogen or C1-C6 alkyl, heterocyclic or aryl (C1-C6 alkyl)-, R5 and R6 when taken together with the nitrogen atom to which they are attached from an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring.
• Structure–activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2′ and P3′ side chains
  作者：Stephen J. Davies、Andrew P. Ayscough、R.Paul Beckett、John M. Clements、Sheila Doel、Lisa M. Pratt、Zoë M. Spavold、S.Wayne Thomas、Mark Whittaker

  DOI：10.1016/s0960-894x(03)00533-x

  日期：2003.8

  Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to both the P2' and P3' side chains. Enzyme inhibition and antibacterial activity data revealed that a variety of substituents are tolerated at the P2' and P3' positions of the inhibitor backbone. The data from this study highlights the potential for modification at the P2' and P3' positions to optimise the physicochemical properties. (C) 2003 Elsevier Ltd. All rights reserved.